has function has role vaccinated in route immunizes against disease immunizes recipient breast cancer Homo sapiens therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role intradermal route breast cancer vaccine therapeutic cancer vaccine multi-epitope HER2 peptide vaccine TPIV100 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6317 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525 Jie Zheng Gene name: HER2 Hayleigh Kahn 6317 cancer vaccine 2064 NCT: https://clinicaltrials.gov/study/NCT04197687 A cancer vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer.